Interpace Diagnostics

Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q2 2021

Earnings data Q3 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q2 2019 Results - Earnings Call Transcript

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q4 2018 Results - Earnings Call Transcript

News for Interpace Diagnostics Stock (IDXG)